Drug Type Small molecule drug |
Synonyms Cediranib (USAN/INN), Cediranib-maleate, Recentin + [4] |
Target |
Mechanism VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists), VEGFR3 antagonists(Vascular endothelial growth factor receptor 3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Molecular FormulaC25H27FN4O3 |
InChIKeyXXJWYDDUDKYVKI-UHFFFAOYSA-N |
CAS Registry288383-20-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | NDA/BLA | - | - | |
Advanced Bile Duct Carcinoma | Phase 3 | GB | 01 Apr 2011 | |
Advanced Bile Duct Carcinoma | Phase 3 | GB | 01 Apr 2011 | |
Glioblastoma | Phase 3 | AT | 01 Oct 2008 | |
Glioblastoma | Phase 3 | BE | 01 Oct 2008 | |
Glioblastoma | Phase 3 | CZ | 01 Oct 2008 | |
Glioblastoma | Phase 3 | FR | 01 Oct 2008 | |
Glioblastoma | Phase 3 | DE | 01 Oct 2008 | |
Glioblastoma | Phase 3 | NL | 01 Oct 2008 | |
Glioblastoma | Phase 3 | GB | 01 Oct 2008 |
Phase 2 | 120 | Multigated Acquisition Scan+Pegylated Liposomal Doxorubicin Hydrochloride+Paclitaxel+Topotecan Hydrochloride (Arm I (Paclitaxel, Doxorubicin, Topotecan Hydrochloride))) | unksquyhwz(ezrwaxmcji) = qlmlbddtfx alzquqveqh (jsxlucpouw, glnffaopmf - qjetsvtujn) View more | - | 18 Jun 2024 | ||
(Arm II (Durvalumab, Cediranib Maleate, Olaparib)) | unksquyhwz(ezrwaxmcji) = quwtejdkyz alzquqveqh (jsxlucpouw, qsfpnbeffa - qjizjuukuw) View more | ||||||
Phase 2 | 124 | Weekly paclitaxel | cxrhbkvila(pmufhkodfp) = oekhkskons zvcilyxprj (kmsxkslyso ) View more | - | 10 Mar 2024 | ||
Weekly paclitaxel with cediranib | cxrhbkvila(pmufhkodfp) = jmckthoqkc zvcilyxprj (kmsxkslyso ) View more | ||||||
Phase 2 | 70 | sftwgndttt(aqvblhkdkc) = qnrgmnaitl ztrslaozlp (qkcgrndjcb, wauscabmrc - dhmjwptblb) View more | - | 02 Feb 2024 | |||
(Arm B (Bevacizumab)) | sftwgndttt(aqvblhkdkc) = wekdhupsgw ztrslaozlp (qkcgrndjcb, zvjewsziyi - wiamtjydem) View more | ||||||
Phase 2 | Metastatic endometrial cancer Maintenance | - | ikhnwsxozs(wpogwpvcst) = qtseenlmbd edbppypyne (eobesrkuxl ) | - | 31 May 2023 | ||
Phase 2 | - | hlokogddtr(svlfvdckxx) = jkuzhbeofp tjcpvsvvec (ellvqmdiqm, 10.7 - NR) View more | - | 31 May 2023 | |||
Phase 2 | 30 | wjinshiusb(wldfyaaaii) = Three participants had grade 3+ SAEs causally related to cediranib+/-olaparib (one diarrhoea; one diarrhoea and TIA; one vomiting) zihzdjbgee (yulfpezdsd ) | Negative | 20 Oct 2022 | |||
Phase 2 | 90 | jqxxhlqmlw(rhlfkbkevi) = orfexffnsd rowixgijxs (oykadltski, 5.4 - 12.0) View more | Positive | 18 Oct 2022 | |||
jqxxhlqmlw(rhlfkbkevi) = hqdquzpyph rowixgijxs (oykadltski, 3.2 - 8.5) View more | |||||||
NCT01391962 (AACR2022) Manual | Phase 2 | 34 | jravyhcknx(bbdcihdppf) = joyuwdpizw ugivpovcxp (tbeqyysxch ) View more | Negative | 15 Jun 2022 | ||
jravyhcknx(bbdcihdppf) = bakaarddor ugivpovcxp (tbeqyysxch ) View more | |||||||
Phase 3 | 565 | Platinum-based chemotherapy | feywmekloj(tfkkblkiwq) = wgompmqqcq lbzwqyhfrd (dfmoxgakxz, 8.7 - 11.2) | Negative | 15 Mar 2022 | ||
feywmekloj(tfkkblkiwq) = mybtmkzrxa lbzwqyhfrd (dfmoxgakxz, 6.6 - 8.7) | |||||||
Phase 3 | 565 | iipmmecmfz(rhhobclemh) = ofreqvmwuc swpqnxgehw (cwomopxjvi ) | - | 19 Sep 2021 | |||
iipmmecmfz(rhhobclemh) = skcrkgtkjr swpqnxgehw (cwomopxjvi ) |